주식/증권
📉 부정적
This Biotech Stock Plunges 48%. Its Sickle Cell Drug Has ‘No Viable Path Forward.’
요약
Fulcrum Therapeutics discontinues its pociredir program after the Food and Drug Administration raises concerns.